Noticias y Actividades de CervoMed

CervoMed es una empresa que cotiza bajo el símbolo de cotización CRVO (US).

Ver el organigrama con sus 14 ejecutivos principales

Biografías más buscadas en CervoMed

• John Alam, Chief Executive Officer
• Frank Zavrl, Director
• Marwan Sabbagh, Director

Recientes movimientos de ejecutivos en CervoMed

• Mark De Rosch se incorporará a la empresa como Executive Vice President, Regulatory and Government Affairs and Program Management el 1 de may.. de 2025  (noticia publicada el 23 de abril de 2025).
• Robert Cobuzzi, Chief Operating Officer and Director, abandonará la empresa el 1 de jul.. de 2025  (noticia publicada el 23 de abril de 2025).
• Kelly Blackburn que ha sido Senior Vice President, Clinical Development, ha ascendido a Executive Vice President, Clinical Development  (noticia publicada el 23 de abril de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en CervoMed.

CervoMed tiene 1.824 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Roche (Suiza).

Popular M&A news in Farmacia

• Cyclo Therapeutics ha Rafael Holdings adquirido (publicado el 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Jean-Michel Demeure - Vice President, Finance Global Operations en Sanofi

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de CervoMed

• Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 | CervoMed
• CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) | CervoMed
• CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates | CervoMed
• CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies | CervoMed
• CervoMed to Present at the 8th International Lewy Body Dementia Conference | CervoMed
• CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference | CervoMed
• CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies | CervoMed
• News Releases | CervoMed
• CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CervoMed
• CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia | CervoMed
• View more press releases Close

Redes sociales sobre CervoMed

• CervoMed en Wikipedia, Google News y Yahoo Finance
• CervoMed en LinkedIn, Twitter y YouTube